Af­ter 13% dis­count In­nate Phar­ma rais­es $69M; AZTher­a­pies bags $26.3M from Se­ries C fi­nanc­ing round

→ As­traZeneca-part­nered French biotech In­nate Phar­ma — which was shoot­ing for a $100 mil­lion IPO by of­fer­ing 10.7 mil­lions shares at $7.50 per share last month — has raised $69 mil­lion in the US by of­fer­ing 12.5 mil­lion shares at $5.50 (€4.97), a 13% dis­count to its pri­or clos­ing price on Eu­ronext Paris (€5.71; tick­er $IPH). Citi, SVB Leerink and Ever­core ISI were the lead man­agers. The com­pa­ny plans to list on the Nas­daq un­der the sym­bol $IPHA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER